2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Immunotherapy, Adverse Events, Biological Processes, Genomics, Hematopoiesis, Clinical Practice (Health Services and Quality), Practice Models, Diseases, Bleeding and Clotting, Thrombocytopenias, Bone Marrow Failure Syndromes, Aplastic Anemia, Hemoglobinopathies, Immunology, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Aggressive Lymphoma, Research, AML, MDS, MPN, Clinical Research, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric
PAPER

2534 Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements underwent allogeneic hematopoietic stem cell transplantation

Yibo Wu Sr, MD,, Xiaoyu Lai2, Lizhen Liu3, Xiaolin Yuan4, Luxin Yang5, Lin Li6, Jimin Shi7, Yanmin Zhao8, Panpan Zhu9, Jian Yu10, He Huang, MD, PhD11, Shanshan Pei, PhD12, Yi Luo13
1 Liangzhu Laboratory, Hangzhou, China, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Zhejiang University, Hangzhou, China
2 Liangzhu Laboratory, Hangzhou, China, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Zhejiang University, Hangzhou, China
3 Liangzhu Laboratory, Hangzhou, China, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Zhejiang University, Hangzhou, China
4 Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China
5 Liangzhu Laboratory, Hangzhou, China, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Zhejiang University, Hangzhou, China
6 Liangzhu Laboratory, Hangzhou, China, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Zhejiang University, Hangzhou, China
7 Liangzhu Laboratory, Hangzhou, China, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Zhejiang University, Hangzhou, China
8 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
9 Liangzhu Laboratory, Hangzhou, China, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Zhejiang University, Hangzhou, China
10 Liangzhu Laboratory, Hangzhou, China, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Zhejiang University, Hangzhou, China
11 Liangzhu Laboratory, Hangzhou, China, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Zhejiang University, Hangzhou, China
12 Liangzhu Laboratory, Hangzhou, China, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Zhejiang University, Hangzhou, China
13 Liangzhu Laboratory, Hangzhou, China, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Zhejiang University, Hangzhou, China

Background:

Acute myeloid leukemia (AML) with rearrangement of the lysine methyltransferase 2a gene (KMT2A-r) has adverse outcomes. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the primary curative approach; however, among patients who receive allo-HSCT, reports on the prognostic impact of various KMT2A translocations remain conflicting, and less is known regarding the role of co-occurring mutations.

Methods: 

A total of 148 adult patients with KMT2A-r AML who underwent allo-HSCT between January 2016 and June 2026 were included in this study. The primary endpoint was cumulative incidence of relapse (CIR); secondary endpoints included overall survival (OS) and disease-free survival (DFS). Measurable residual disease (MRD) was assessed using quantitative real-time polymerase chain reaction (qRT-PCR).

Results:

Among the 148 patients, the median age was 40 years (range, 18–66). There were 73 (49.3%) males and 75 (50.7%) females. Seventeen (11.5%) underwent matched sibling donor (MSD) transplantation, 24 (16.2%) received matched unrelated donor (MUD) transplantation, and 107 (72.3%) underwent haploidentical donor transplantation. The most common fusion partners were KMT2A::MLLT3 (30.4%), KMT2A::MLLT4 (22.9%), KMT2A::ELL (22.9%), and KMT2A::MLLT10 (10.8%), with other partners accounting for 12.8%. With a median follow-up of 629 days (range, 34–3743) post-transplantation, the 2-year CIR, DFS, and OS rates were 31.2% (95% CI: 22.4–44.4), 54.5% (95% CI: 45.5–63.5), and 73.8% (95% CI: 65.4–82.2), respectively.

The 2-year relapse rate was significantly higher in the KMT2A::MLLT4 group [55.8% (95% CI: 29.7–75.5)] compared with the KMT2A::MLLT3 [25.5% (95% CI: 12.9–40.2)], ELL [17.4% (95% CI: 4.6–36.9)], and MLLT10 [14.0% (95% CI: 8.7–58.3)] groups (P = 0.001). Patients with KRAS mutations had a significantly higher 2-year CIR (50.8% [95% CI: 26.5–70.9] vs 26.1% [95% CI: 17.0–36.1], P = 0.012). By contrast, neither FLT3 mutations (12.3% [95% CI: 1.7–34.0] vs 34.4% [95% CI: 24.5–44.5], P = 0.10) nor NRAS mutations (34.8% [95% CI: 15.3–55.3] vs 30.2% [95% CI: 20.5–40.5], P = 0.37) significantly impacted CIR.

Pre-transplant KMT2A-r MRD positivity was predictive of significantly higher 2-year CIR [60.9% (95% CI:30.1–81.5) vs 25.9% (95% CI:16.4–35.1), P = 0.003], reduced DFS [34.9% (95% CI:14.3–55.5) vs 59.3% (95% CI:49.3–69.3), P = 0.006], and inferior OS [50.0% (95% CI:26.7–73.3) vs 78.7% (95% CI:70.1–87.3), P = 0.003]. No significant differences in 2-year CIR were observed across transplant types [MSD: 35.0% (95% CI:11.5–60.1); MUD: 33.3% (95% CI:13.5–54.7); haploidentical: 29.3% (95% CI:19.1–40.3); P = 0.92]. Post-transplantation azacitidine prophylaxis was not associated with a reduced 2-year CIR [29.3% (95% CI:12.3–48.7) vs 33.5% (95% CI:23.2–44.1) in the non-intervention group, P = 0.17]; however, it significantly extended 2-year OS [88.9% (95% CI:76.9–100.0) vs 67.7% (95% CI:57.3–78.1), P = 0.043]. Multivariable analysis confirmed KRAS mutation and pre-HSCT MRD status as independent predictors of relapse and mortality.

Conclusions:

Despite receiving allo-HSCT, KMT2A-r AML remains associated with adverse outcomes, particularly in the presence of KRAS mutations. Therefore, effective interventions are urgently needed to reduce post-transplant relapse in this high-risk population.

Keywords: acute myeloid leukemia; allogeneic hematopoietic stem cell transplantation; KMT2A rearrangement; measurable residual disease; KRAS mutation

Yibo Wu Sr, MD,: No relevant conflicts of interest to declare.